285 related articles for article (PubMed ID: 10635303)
21. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
22. The role of acute-phase reactant proteins, carcinoembryonic antigen and CA 19-9 as a marker in the preoperative staging of colorectal cancer: a prospective clinical study.
Yüceyar S; Ertürk S; Dirican A; Cengiz A; Saner H
Int Surg; 1996; 81(2):136-9. PubMed ID: 8912078
[TBL] [Abstract][Full Text] [Related]
23. Mutant p53 protein in the serum of patients with colorectal cancer: Correlation with the level of carcinoembryonic antigen and serum epidermal growth factor receptor.
Abdel-Aziz MM; Lotfy M; El-Kady IM; Abozaid M
Cancer Detect Prev; 2009; 32(4):329-35. PubMed ID: 16632243
[TBL] [Abstract][Full Text] [Related]
24. Tumor markers in staging and prognosis of colorectal carcinoma.
Levy M; Visokai V; Lipska L; Topolcan O
Neoplasma; 2008; 55(2):138-42. PubMed ID: 18237252
[TBL] [Abstract][Full Text] [Related]
25. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract][Full Text] [Related]
26. [Evaluation of combined CA-19-9 and CEA assay in monitoring recurrences and metastases of colorectal cancer].
Yu BM
Zhonghua Wai Ke Za Zhi; 1992 Dec; 30(12):707-9, 777. PubMed ID: 1339738
[TBL] [Abstract][Full Text] [Related]
27. Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection.
Tang R; Yeh CY; Wang JY; Changchien CR; Chen JS; Hsieh LL
Ann Surg Oncol; 2009 Sep; 16(9):2516-23. PubMed ID: 19565285
[TBL] [Abstract][Full Text] [Related]
28. [Prognostic study of preoperative serum levels of CEA and CA 19-9 in colorectal cancer].
Uehara M; Manaka D; Baba S; Oji Y; Hirata K; Shimizu M; Noguchi M
Gan To Kagaku Ryoho; 2007 Sep; 34(9):1413-7. PubMed ID: 17876139
[TBL] [Abstract][Full Text] [Related]
29. [Antigens (CEA and CA 19-9) in diagnosis and prognosis colorectal cancer].
Grotowski M
Pol Merkur Lekarski; 2002 Jan; 12(67):77-80. PubMed ID: 11957811
[TBL] [Abstract][Full Text] [Related]
30. [The clinical significance of serum anti-p53 antibody as a monitoring marker in colorectal cancer].
Amano K; Kumamoto K; Kuwabara K; Ishiguro T; Ohsawa T; Okada N; Kumagai Y; Baba H; Ishibashi K; Tsuji Y; Haga N; Ishida H
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2170-2. PubMed ID: 23268013
[TBL] [Abstract][Full Text] [Related]
31. [The pre- and postoperative monitoring of the immunological indices and tumor markers in colorectal carcinoma].
Iarŭmov N; Ignatov A; Viiachki I
Khirurgiia (Sofiia); 1998; 51(3):42-8. PubMed ID: 9974027
[TBL] [Abstract][Full Text] [Related]
32. The significance of CEA, CA19-9 and CA72-4 in the detection of colorectal carcinoma recurrence.
Holubec L; Topolcan O; Pikner R; Pecen L; Vaclavickova J; Wirthova M; Molacek J; Stieber P; Holdenrieder S; Sen LH; Finek J
Anticancer Res; 2000; 20(6D):5237-44. PubMed ID: 11326702
[TBL] [Abstract][Full Text] [Related]
33. [Usefulness of evaluation of carcinoembryonic antigen (CEA) and soluble fragments of cytokeratin 18-th (TPS) in postoperative monitoring of patients with colorectal cancer].
Sandelewski A; Kokocińska D; Partyka R; Kocot J; Starzewski J; Chanek I; Jałowiecki P
Pol Merkur Lekarski; 2005 Jun; 18(108):647-50. PubMed ID: 16124375
[TBL] [Abstract][Full Text] [Related]
34. Identification of Cystatin SN as a novel tumor marker for colorectal cancer.
Yoneda K; Iida H; Endo H; Hosono K; Akiyama T; Takahashi H; Inamori M; Abe Y; Yoneda M; Fujita K; Kato S; Nozaki Y; Ichikawa Y; Uozaki H; Fukayama M; Shimamura T; Kodama T; Aburatani H; Miyazawa C; Ishii K; Hosomi N; Sagara M; Takahashi M; Ike H; Saito H; Kusakabe A; Nakajima A
Int J Oncol; 2009 Jul; 35(1):33-40. PubMed ID: 19513549
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic value of serum tumor markers in asymptomatic individuals.
Eleftheriadis N; Papaloukas C; Pistevou-Gompaki K
J BUON; 2009; 14(4):707-10. PubMed ID: 20148467
[TBL] [Abstract][Full Text] [Related]
36. Increased serum level of sialyl Lewis(x) antigen in blood from the tumor drainage vein in patients with non-polypoid growth type of colorectal cancer.
Nakagoe T; Sawai T; Tsuji T; Jibiki M; Ohbatake M; Nanashima A; Yamaguchi H; Kurosaki N; Yasutake T; Ayabe H; Arisawa K
J Exp Clin Cancer Res; 2001 Mar; 20(1):85-90. PubMed ID: 11370835
[TBL] [Abstract][Full Text] [Related]
37. The clinical efficacy of CA 72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA.
Kodama I; Koufuji K; Kawabata S; Tetsu S; Tsuji Y; Takeda J; Kakegawa T
Int Surg; 1995; 80(1):45-8. PubMed ID: 7657491
[TBL] [Abstract][Full Text] [Related]
38. A comparison of tumour M2-PK with carcinoembryonic antigen and CA19-9 in patients undergoing liver resection for colorectal metastases.
Kumar Y; Pinedo IR; Tapuria N; Zabron A; Davidson BR
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1006-11. PubMed ID: 18787469
[TBL] [Abstract][Full Text] [Related]
39. Accuracy of the preoperative determination of tumor markers in the differentiation of liver mass lesions in surgical patients.
Torzilli G; Makuuchi M; Ferrero A; Takayama T; Hui AM; Abe H; Inoue K; Nakahara K
Hepatogastroenterology; 2002; 49(45):740-5. PubMed ID: 12063982
[TBL] [Abstract][Full Text] [Related]
40. [Clinical significance of serum p53 antibody detection in a chemosensitivity assay in cases of human colorectal cancer].
Takeda A; Shimada H; Nakajima K; Imaseki H; Okazumi S; Takayama W; Iwasaki K; Makino H; Natsume T; Kouno T; Kondo S; Suzuki T; Ochiai T; Isono K
Gan To Kagaku Ryoho; 2000 Jun; 27(6):879-83. PubMed ID: 10897215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
